- Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru,
- Faculty of Medicine, Universidad CES, Medellin, Colombia.
Correspondence Address:
Jose Daniel Flores-Sanchez, Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.
DOI:10.25259/SNI_744_2023
Copyright: © 2023 Surgical Neurology International This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.How to cite this article: Jose Daniel Flores-Sanchez1, Daniela Alejandra Perez-Chadid2, John Vargas-Urbina1, Jorge Zumaeta1, Rommel Roger Rodriguez1, Fernando Palacios1, Jerson Flores-Castillo1. Pandemic impact on aneurysmal subarachnoid hemorrhage in Peru’s high COVID-19 lethality setting: A public institutional experience. 22-Dec-2023;14:440
How to cite this URL: Jose Daniel Flores-Sanchez1, Daniela Alejandra Perez-Chadid2, John Vargas-Urbina1, Jorge Zumaeta1, Rommel Roger Rodriguez1, Fernando Palacios1, Jerson Flores-Castillo1. Pandemic impact on aneurysmal subarachnoid hemorrhage in Peru’s high COVID-19 lethality setting: A public institutional experience. 22-Dec-2023;14:440. Available from: https://surgicalneurologyint.com/?post_type=surgicalint_articles&p=12680
Abstract
Background: The COVID-19 pandemic in 2020 profoundly impacted healthcare worldwide, and Peru was particularly affected, experiencing the highest COVID-19 case fatality rate globally.
Methods: We conducted a retrospective comparative study of patients presenting with aneurysmal subarachnoid hemorrhage (SAH) at a public Peruvian national referral center specializing in cerebrovascular diseases. Two study periods were considered, one during the first wave of the COVID-19 pandemic and a second identical period in 2019. Variables included patient demographics, comorbidities, COVID-19 infection status, clinical presentation, treatment approaches, and hospital outcomes.
Results: We analyzed 114 patients with aneurysmal SAH, 65 (57.0%) treated in 2019 and 49 (43.0%) in 2020. The mean time from emergency admission to the day of definitive treatment during 2019 and 2020 was 2.72 and 1.93 days, respectively. Likewise, the mean time from symptom onset to the date of definitive treatment was 6.71 and 7.70 days, respectively. We identified significant associations between complications such as sepsis, respiratory failure, acute kidney failure, and hospital mortality. The proportion of fatalities was significantly higher in 2020 compared to 2019 (36.7% vs. 15.4%, respectively). Interestingly, there was no statistically significant association between COVID-19 infection status and mortality during the 2020 period.
Conclusion: Patients with aneurysmal SAH treated during the pandemic had a higher proportion of sepsis, respiratory failure, acute kidney failure, and mortality compared to the pre-pandemic period. Reallocating healthcare resources to prioritize COVID-19 patients may have inadvertently neglected or delayed care for patients with other emergency conditions, such as aneurysmal SAH. This highlights the importance of maintaining adequate care for non-infectious emergencies during a pandemic.
Keywords: COVID-19, Global neurosurgery, Latin America, Neurosurgical capacity, Subarachnoid hemorrhage
INTRODUCTION
Peru is one of the countries most affected by the COVID-19 pandemic. From January 2020 to March 2022, 3,517,260 cases and 210,672 deaths from this disease have been confirmed.
According to the World Health Organization, Peru had the highest case fatality rate in the world due to this infection.[
The main objective of this study is to evaluate the impact of the COVID-19 pandemic on the in-hospital clinical evolution of patients with aneurysmal SAH. Our specific goals are to identify the clinical-epidemiological characteristics of patients with aneurysmal SAH by comparing identical periods (March to October) in 2020 (pandemic context) and 2019 (pre-pandemic context) and to compare hospital stay, complications, functional status at discharge, and in-hospital mortality according to each study period.
MATERIALS AND METHODS
We conducted a retrospective and comparative study. It was performed in a single national referral center specializing in cerebrovascular diseases belonging to Peruvian social health insurance.
Our Institutional Review Board approved our study protocol in accordance with the Helsinki Declaration.
We divided the study into two study periods, one during the first wave of the COVID-19 pandemic (March to October 2020) and a second identical period in 2019. After a careful review of patient records, we included patients older than 18 years of age with aneurysmal SAH, corroborated by computer tomography (CT) angiography, and admitted during the study periods, regardless of the type of treatment performed. For the diagnosis of COVID-19 infection, polymerase chain reaction and chest CT were considered. Patients with incomplete data and those with SAH or intraparenchymal hematoma of different etiology were excluded from the study.
The following variables were assessed: provenance, age, gender, comorbidities (diabetes mellitus, high blood pressure, cancer, and smoking), COVID-19 infection status, clinical stratification at admission (Glasgow coma scale, Fisher scale, and WFNS score), initial symptoms, type of treatment (clipping, endovascular, or none), and hospital stay (including time in days from the onset of SAH symptoms to admission, intervention, and discharge or death). During follow-up, we evaluated clinical complications (pneumonia, sepsis, surgical wound infection, venous thrombosis, electrolyte disorders, and acute respiratory or kidney failure), neurological complications (stroke, rebleeding, delayed cerebral ischemia-clinical vasospasm, and hydrocephalus), functional status at discharge (measured by the modified Rankin scale), and in-hospital mortality.
Statistical analysis
A descriptive analysis was performed using frequencies, percentages, and summary measures (mean, median, and standard deviation). The t-test was used to evaluate the differences between groups of patients in relation to a quantitative characteristic (previous assessment of normality). The Mann–Whitney test was used for the evaluation of quantitative variables with non-normal distribution. The Chi-square test was used to estimate associations between two qualitative variables, applying the Yates correction when appropriate (only when dichotomous variables were evaluated). When the assumption of having a minimum expected value of 5 was not fulfilled, and the variables were not dichotomous, the statistical association was considered not evaluable. A logistic regression method with 95% confidence intervals (CI) was applied to assess the risk of complications, poor functional status, and mortality related to the COVID-19 pandemic exposure. All data were analyzed using the statistical software Statistical Package for the Social Sciences version 25.0 (IBM Corp). A significant statistical association level was set at P < 0.05.
RESULTS
We analyzed records from 114 patients with aneurysmal SAH, 65 (57.0%) from the period March to October 2019 and 49 (43.0%) from the period March to October 2020 [
The mean age of patients during the 2019 and 2020 periods was 57.6 (SD 13.53) and 58.63 (SD 15.28) years, respectively. Female sex predominated in both groups, 42 (64.6%) in 2019 and 39 (79.6%) in 2020. No significant association was found for epidemiological characteristics (gender, age, provenance, high blood pressure, diabetes mellitus, cancer, and smoking) regarding the study periods. There was also no significant statistical association between the clinical characteristics at admission and the study periods.
Of 114 patients included in the study, 45 (39%) underwent surgical clipping, 59 (51.9%) underwent endovascular therapy, and 10 (8.8%) did not receive any treatment [
The mean time from emergency admission to the day of definitive treatment during 2019 and 2020 was 2.72 (SD 6.65) and 1.93 (SD 2.40) days, respectively. Likewise, the mean time from symptom onset to the date of definitive treatment in both periods was 6.71 (SD 9.37) and 7.70 (SD 13.25) days, respectively. When evaluating these variables, we found no significant difference between the study periods [
Length of hospital stay, complications, functional status at discharge, and hospital mortality for all cases by period are shown in
Finally, we observed a significantly higher proportion of fatalities in 2020 than in the 2019 period (36.7% vs. 15.4%, respectively). The likelihood of death was approximately three times higher in patients in the 2020 period (P = 0.009, OR: 3.19, 95% CI: 1.31–7.77) [
Regarding COVID-19 diagnosis, from March to October 2020, 14 (28.6%) cases of infection were reported in patients with aneurysmal SAH [
DISCUSSION
In our study, we observed a decrease in cases of aneurysmal SAH during the first wave of the COVID-19 pandemic (March–October 2020) compared to the 2019 period (49 vs. 65 cases). These findings are similar to those reported by several authors, such as Nguyen et al.,[
For the management of ruptured aneurysms, we considered the clinical status of the patient and the anatomical characteristics of the aneurysm. The type of treatment performed, whether surgical or endovascular, depended on the logistics available on the patient’s arrival at the hospital. During the 2020 period, we observed a decrease in the percentage of cases treated by surgical clipping and an increase in patients undergoing endovascular therapy [
Another interesting finding in our study corresponds to the time observed from the onset of symptoms to definitive treatment. In both study periods, the mean of this interval was between 6 and 8 days (slightly longer in the 2020 subgroup, without statistical significance), with a mean time from hospital admission to definitive treatment of about 2.5 days. A multicenter study conducted in Italy[
Regarding the evolution of the patients, it is important to remember that depending on the context, sepsis and septic shock can have a mortality rate of>40%. In addition, in patients with aneurysmal SAH, the risk of sepsis and systemic inflammatory response syndrome may be >50%.[
Ates et al.[
Qureshi et al.[
The SVIN COVID-19 Global SAH Registry [
Multiple studies have observed that the reorganization of resources for the medical care of patients with COVID-19 has triggered involuntary neglect of those patients without the infection who are in an emergency condition due to other causes.[
Finally, as lessons learned from this experience, we believe that it is essential to take action with regard to the following: First, we must always maintain strict surveillance for patients with SAH, especially after receiving the definitive surgical or endovascular treatment. Second, it is necessary to increase the number of ICU beds nationwide, ensuring the necessary equipment and supplies for the monitoring of neurosurgical patients. Third, to properly manage patients with SAH and other types of acute cerebrovascular emergencies, stroke units should be established and strengthened in the nation’s major hospitals across all regions. Finally, an efficient referral system should be maintained for the timely transfer of patients in neurosurgical emergency conditions to centers with higher levels of complexity.
Limitations
Limitations of this study included the retrospective methodology and the size of the population that was considered. Due to the small number of people in the subgroup of patients with COVID-19 during the 2020 period, we were unable to perform a statistical analysis to assess the specific role of COVID-19 infection in the prognosis of patients with aneurysmal SAH. However, this study allowed us to assess the impact of the COVID-19 pandemic in the context of our healthcare system. More similar studies with a larger population would be necessary to perform an analysis with greater statistical power.
CONCLUSION
Peru has been significantly impacted by the COVID-19 pandemic, currently holding the unenviable distinction of having the highest case fatality rate across the globe. This has resulted in extensive challenges for Peru’s healthcare system and economy, as well as for the wider population.
During the COVID-19 pandemic, there was a decrease in aneurysmal SAH admissions and a proportional decline in aneurysm surgical clipping for ruptured aneurysms. Moreover, there was an increase in the rate of coiling, suggesting a shift toward endovascular therapy during the pandemic.
We did not find a statistically significant association between COVID-19 infection and worse outcomes in patients with aneurysmal SAH in the subgroup evaluated during the pandemic. Nevertheless, the overall analysis found a significantly higher proportion of cases of sepsis, respiratory failure, acute kidney failure, and mortality in patients with aneurysmal SAH treated in the context of the COVID-19 pandemic when compared with the pre-pandemic period. We did not observe significant differences in terms of neurological complications, hospital stay, or functional status when comparing both study periods.
The reorganization of the health system’s resources for the treatment of patients during a major pandemic can lead to the involuntary neglect of those patients who are in emergencies for other reasons. Attention must be focused on the importance of strict surveillance for SAH patients, increasing ICU beds nationwide, strengthening stroke units in major hospitals, and maintaining an efficient referral system for the timely transfer of neurosurgical emergency patients.
Ethical approval
The author(s) declare that they have taken the ethical approval from IRB, N° 42-IETSI-ESSALUD-2020, Research Ethics Committee Specific to COVID-19.
Declaration of patient consent
Patients’ consent not required as patients’ identities were not disclosed or compromised.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation
The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.
Disclaimer
The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Journal or its management. The information contained in this article should not be considered to be medical advice; patients should consult their own physicians for advice as to their specific medical needs.
References
1. Aggarwal G, Lippi G, Henry BM. Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature. Int J Stroke. 2020. 15: 385-9
2. Ates O, Yilmaz I, Karaarslan N, Ersoz E, Hacioglu Kasim FB, Dogan M. Coexistence of SARS-CoV-2 and cerebrovascular diseases: Does COVID-19 positivity trigger cerebrovascular pathologies?. J Infect Dev Ctries. 2022. 16: 981-92
3. Batcik OE, Kanat A, Cankay TU, Ozturk G, Kazancıoglu L, Kazdal H. COVID-19 infection produces subarachnoid hemorrhage; acting now to understand its cause: A short communication. Clin Neurol Neurosurg. 2021. 202: 106495
4. Benger M, Williams O, Siddiqui J, Sztriha L. Intracerebral haemorrhage and COVID-19: Clinical characteristics from a case series. Brain Behav Immun. 2020. 88: 940-4
5. Bernat AL, Giammattei L, Abbritti R, Froelich S. Impact of COVID-19 pandemic on subarachnoid hemorrhage. J Neurosurg Sci. 2020. 64: 409-10
6. Boeris D, Falco J, Potenza A, Colistra D, Bagnoli E, Cenzato M. Workflow management for COVID-19 patients needing an urgent neurosurgical procedure. J Neurosurg Sci. 2020. 64: 407-9
7. Czeisler MÉ, Marynak K, Clarke KE, Salah Z, Shakya I, Thierry JM. Delay or avoidance of medical care because of COVID-19-related concerns-United States, June 2020. MMWR Morb Mortal Wkly Rep. 2022. 69: 1250-7
8. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020. 382: 2049-55
9. Fiorindi A, Vezzoli M, Doglietto F, Zanin L, Saraceno G, Agosti E. Aneurismal subarachnoid hemorrhage during the COVID-19 outbreak in a Hub and Spoke system: Observational multicenter cohort study in Lombardy, Italy. Acta Neurochir (Wien). 2022. 164: 141-50
10. Flinspach AN, Konczalla J, Seifert V, Zacharowski K, Herrmann E, Balaban Ü. Detecting sepsis in patients with severe subarachnoid hemorrhage during critical care. J Clin Med. 2022. 11: 4229
11. Flores-Sanchez JD, Saal G, Zumaeta J, Palacios F, Rodriguez R, Molina C. Comparison of surgical and endovascular treatment of posterior communicating segment aneurysms. Surg Neurol Int. 2020. 11: S7-16
12. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. 382: 1708-20
13. Güresir E, Gräff I, Seidel M, Bauer H, Coch C, Diepenseifen C. Aneurysmal subarachnoid hemorrhage during the shutdown for COVID-19. J Clin Med. 2022. 11: 2555
14. Hartnett KP, Kite-Powell A, DeVies J, Coletta MA, Boehmer TK, Adjemian J. Impact of the covid-19 pandemic on emergency department visits-United States, January 1, 2019-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020. 69: 699-704
15. Kashefiolasl S, Qasem LE, Brawanski N, Funke M, Keil F, Hattingen E. Impact of COVID-19 pandemic on treatment management and clinical outcome of aneurysmal subarachnoid hemorrhage-a single-center experience. Front Neurol. 2022. 13: 836422
16. Lange SJ, Ritchey MD, Goodman AB, Dias T, Twentyman E, Fuld J. Potential indirect effects of the COVID-19 pandemic on use of emergency departments for acute life-threatening conditions-United States, January-May 2020. MMWR Morb Mortal Wkly Rep. 2020. 69: 795-800
17. Lee MS, Park CG, Hughes TL, Jun SE, Whang K, Kim N. The predictive role of health-promoting behaviours and perceived stress in aneurysmal rupture. J Clin Nurs. 2018. 27: e1068-77
18. Ministerio de Salud del Per. Tiempos de pandemia 2020-2021. 2021. p. Available from: http://bvs.minsa.gob.pe/local/MINSA/5485.pdf [Last accessed on 2022 Sep 11]
19. Mogharab V, Ostovar M, Ruszkowski J, Hussain SZ, Shrestha R, Yaqoob U. Global burden of the COVID-19 associated patient-related delay in emergency healthcare: A panel of systematic review and meta-analyses. Global Health. 2022. 18: 58
20. Nguyen TN, Haussen DC, Qureshi MM, Yamagami H, Fujinaka T, Mansour OY. Decline in subarachnoid haemorrhage volumes associated with the first wave of the COVID-19 pandemic. Stroke Vasc Neurol. 2021. 6: 542-52
21. Nguyen TN, Jadhav AP, Dasenbrock HH, Nogueira RG, Abdalkader M, Ma A. Subarachnoid hemorrhage guidance in the era of the COVID-19 pandemic-an opinion to mitigate exposure and conserve personal protective equipment. J Stroke Cerebrovasc Dis. 2020. 29: 105010
22. Nogueira RG, Abdalkader M, Qureshi MM, Frankel MR, Mansour OY, Yamagami H. Global impact of COVID-19 on stroke care. Int J Stroke. 2021. 16: 573-84
23. Qureshi AI, Baskett WI, Huang W, Shyu D, Myers D, Lobanova I. Subarachnoid hemorrhage and COVID-19: An analysis of 282,718 patients. World Neurosurg. 2021. 151: e615-20
24. Reddy ST, Garg T, Shah C, Nascimento FA, Imran R, Kan P. Cerebrovascular disease in patients with COVID-19: A review of the literature and case series. Case Rep Neurol. 2020. 12: 199-209
25. Santi L, Golinelli D, Tampieri A, Farina G, Greco M, Rosa S. Non-COVID-19 patients in times of pandemic: Emergency department visits, hospitalizations and cause-specific mortality in Northern Italy. PLoS One. 2021. 16: e0248995
26. SVIN COVID-19 Global SAH Regist. Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up. J Neurol Neurosurg Psychiatry. 2022. 93: 1028-38
27. WHO. Coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int [Last accessed on 2022 Mar 02].
28. Yoshimoto T, Yamagami H, Sakai N, Toyoda K, Hashimoto Y, Hirano T. Impact of COVID-19 on the volume of acute stroke admissions: A nationwide survey in Japan. Neurol Med Chir (Tokyo). 2022. 62: 369-76